• Explore /
  • Poster
  • / Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.

Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.

Abstract Poster

Authors

Vivek Subbiah

Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX

Vivek Subbiah , Martin Gutierrez , Carey K. Anders , George Ansstas , Taofeek K. Owonikoko , Varun Monga , Peter A. J. Forsyth , Ibiayi Dagogo-Jack , Sunandana Chandra , Katy K. Tsai , Eli L. Diamond , Meredith McKean , Elizabeth Iannotti Buchbinder , Dale Nepert , Kim Ingram , Colleen Oliver , Micaela Reddy , Kati Maharry , Yan Xing

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04543188

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS3152)

DOI

10.1200/JCO.2021.39.15_suppl.TPS3152

Abstract #

TPS3152

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Dejan Juric

First Author: Meredith McKean

First Author: Sarina A. Piha-Paul

First Author: Gregory J. Riely